Jennifer Rosendin has expertise in valuation of intellectual property, economic and financial modeling, and statistical analyses. Ms. Rosendin applies her expertise in conducting rigorous analyses to high-stakes commercial litigation and assisting clients in evaluating complex business decisions. She provides analyses on issues including reasonable royalties, lost profits, unjust enrichment, commercial success, irreparable harm, labor and employment, licensing, injunctive relief, valuation, and business analytics.
Ms. Rosendin has expertise and experience across various industries, including electronics (microprocessors, computers, and mobile devices), the life sciences (medical devices, pharmaceuticals, and medical testing), telecommunications, financial services, entertainment, e-commerce, retail, and sports.
A few examples of Ms. Rosendin’s work include the following projects:
Patent damages for microprocessor technology: Analyzed damages for alleged infringement of patented microprocessor technologies, including econometric modeling and assessment of the economic contribution of the patented technology to revenues and profits, commercialization apportionment, and a reasonable royalty.
Damages for alleged breach of contract and patent infringement of prenatal testing technology: Analyzed damages related to breach claims and patent infringement claims involving non-invasive prenatal testing (NIPT) technology, including valuation modeling, revenue forecasting, and analysis of lost profits, marketplace expansion and segmentation, licensing and distribution, marketing and promotional effects, and a reasonable royalty.
Damages analysis related to alleged employee raid: Assessed lost profits and unjust enrichment damages resulting from an alleged raid of nearly 200 employees from a financial institution and misappropriation of trade secrets. Economic issues addressed included revenue forecasting, profitability, apportionment, valuation of an investment strategy, marketplace competition, lost profits, and unjust enrichment damages.
Evaluation of irreparable harm in the context of a preliminary injunction against a medical device: Analyzed sales and market data to determine quantification of potential damages, including issues relating to nexus, market share loss, price erosion, and reputational effects. Also considered the impact of the device on public interest and balance of harms.
Evaluation of a potential at-risk drug launch for a generic pharmaceutical company: Forecasted the potential lost profits and reasonable royalty damages exposure that could result from launching generic drugs at-risk. Developed parameterized model to estimate potential damages under various scenarios, including varying degrees of generic competition and price erosion, launch timing, and the presence of an authorized generic.
Before joining Secretariat, Ms. Rosendin was a vice president at Intensity. She has also served as an economist for a large global professional services corporation focused on government infrastructure and development. In this capacity, her work focused on measuring the economic effects of U.S. government-funded road, water, and electricity projects in Afghanistan, Iraq, and South Sudan.